



Answers to questions left unanswered during the course

Wednesday 12 May 2024

Question to Aurelia Nguyen

1. What is the plan GAVI for AEFI or vaccine safety monitoring?

⇒ *Gavi provides support to countries for planning, training of front-line health workers and communication activities to facilitate safe and effective introduction of new vaccines. As part of introductions, this may include refresher training on important messages related to common side effects of new vaccines, the importance of reporting these in national AEFI monitoring systems and proactively sharing messages with mothers and caretakers on the side effects that may occur following immunization. Implementation of AEFI and vaccine safety monitoring are the responsibility of countries, typically national immunization programmes and often engagement of national regulatory authorities.*

Questions to Christoph Steffen

1. Is there collaboration between different companies/groups to come up with Highly Effective Vaccine against Mycobacterium Tuberculosis ?

⇒ *I am not a specialist of this topic. Find link to the current TB vaccine pipeline.*
<https://www.tbvi.eu/what-we-do/pipeline-of-vaccines/>

2. About HPV, is it widely used in most countries? How many doses are recommended?

⇒ *The SAGE recommendation: HPV vaccine should be included in all NIP, with primary target girls 9-15 years of age in a 1 or 2 Dose scheme. Global coverage for the first dose of HPV in girls raised from 16% in 2021 to 21% in 2022 (figure for 2023 will be published in July). 138 countries have introduced the HPV vaccine nationally. For more information [click here](#)*